Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01836406

Enrollment

Registered

2013-04-19

Start date

2012-12-31

Completion date

2013-06-30

Last updated

2014-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

ketorolac, remote ischemic preconditioning, partial nephrectomy

Brief summary

Partial nephrectomy is a widely accepted alternative to radical nephrectomy in patients with clinically localized, unilateral renal cell carcinoma and a normal contralateral kidney. Interruption of renal blood flow via pedicle clamping is often necessary during partial nephrectomy, especially for complex tumors with deep parenchymal invasion. Ischemia-reperfusion injury is a complex process involving several mechanisms including renal vasoconstriction, extensive tubular damage and glomerular injury. The investigators will examine the postoperative renal function of patients who received intraoperative ketorolac and remote ischemic preconditioning during partial nephrectomy.

Interventions

DRUGKetorolac tromethamine and remote ischemic preconditioning

Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* ASA l and ll * age 20-65 * patients undergoing partial nephrectomy

Exclusion criteria

* preoperative liver or renal dysfunction, * coagulopathy, * chronic alcoholism, * hypersensitivity of NSAID, * history of warfarin, * history of gastric ulcer

Design outcomes

Primary

Measure	Time frame
serum creatinine	at baseline, 2 hr, 12hr, 24 hr, 48 hr, 72 hr after clamping release

Secondary

Measure	Time frame
Creatinine clearance	at baseline, 2 hr, 12hr, 24 hr, 48 hr, 72 hr after clamping release
urinary NAG	at base line, 2 hr, 12 hr after clamping release
serum NGAL	at base line, 2 hr, 12 hr after clamping release

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026